Esketamine could soon be approved for depression, prompting ‘excitement and hesitation’

dt nasal spray x

The Food and Drug Administration is expected to decide in the coming weeks whether to approve esketamine, which would become the first major depression treatment to hit the market in decades. The psychiatry field is buzzing with excitement — and hesitation.

Esketamine — developed by Johnson & Johnson and delivered as a nasal spray — would be used in combination with oral antidepressants in patients with depression that haven’t responded to other drugs.

But some experts aren’t convinced that there’s enough data just yet to show that esketamine is effective. And they say they want more details on how the drug should be used in the long run.

ADVERTISEMENT

Related article:  5 things to consider with direct-to-consumer health products
[Professor of pharmacy and psychiatry Julie Zito] said that if the drug is approved, she would want to see providers, patients, and the families of patients work together to keep tabs on possible side effects and how well the drug is working.

“The danger is having it so positively portrayed,” [psychiatrist Gerard] Sanacora said. “I’ve been around enough to know this is not necessarily a condition that responds to miracle drugs.”

ADVERTISEMENT
ADVERTISEMENT

Read full, original post: The psychiatry field is buzzing with anticipation — and hesitation — about esketamine for depression

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Here’s where GM crops are grown around the world today

Infographic: Here’s where GM crops are grown around the world today

Do you know where biotech crops are grown in the world? This updated ISAAA infographics show where biotech crops were ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists
Send this to a friend